Safety, Efficacy and Rituximab Levels Following Chemoimmunotherapy (Rituximab plus FAB Chemotherapy) in Children and Adolescents with Mature B-Cell Non-Hodgkin Lymphoma (B-NHL): A Children's Oncology Group Report

被引：0
|
作者：
Cairo, Mitchell S. [1 ]
Lynch, James [2 ]
Harrison, Lauren [1 ]
van de Ven, Carmella [3 ]
Gross, Thomas [4 ]
Shiramizu, Bruce [5 ]
Sanger, Warren [6 ]
Perkins, Sherrie L. [7 ]
Goldman, Stanton [8 ]
机构：
[1] Columbia Univ, Med Ctr, New York, NY 43210 USA
[2] Univ Nebraska Med Ctr, Coll Publ Hlth, Childrens Oncol Grp, Omaha, NE 96822 USA
[3] Columbia Univ, Morgan Stanley Childrens Hosp New York Presbyteri, New York, NY USA
[4] Ohio State Univ, Nationwide Childrens Hosp, Columbus, OH USA
[5] Univ Hawaii, Honolulu, HI USA
[6] Univ Nebraska Med Ctr, Dept Human Genet, Omaha, NE USA
[7] ARUP Labs, Hematopathol Off, Salt Lake City, UT USA
[8] Med City Childrens, Dallas, TX USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：310 / 310
页数：1
相关论文
共 50 条
  • [1] Where is the place for rituximab in the treatment of B-cell non-Hodgkin lymphoma (B-NHL) of children and adolescents?
    Patte, C.
    ANNALS OF ONCOLOGY, 2008, 19 : 110 - 110
  • [2] Safety and pharmacokinetics of rituximab in combination with FAB chemotherapy in children and adolescents with Stage III/IV mature B-NHL and B-cell leukemia ± CNS disease: a Children's Oncology Group Report
    Barth, M. J.
    Goldman, S.
    Zhi, J.
    Smith, L.
    Harrison, L.
    Perkins, S. L.
    Shiramizu, B.
    Gross, T.
    Sanger, W.
    Cairo, M. S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 159 : 23 - 23
  • [3] Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children’s Oncology Group report
    S Goldman
    L Smith
    J R Anderson
    S Perkins
    L Harrison
    M B Geyer
    T G Gross
    H Weinstein
    S Bergeron
    B Shiramizu
    W Sanger
    M Barth
    J Zhi
    M S Cairo
    Leukemia, 2013, 27 : 1174 - 1177
  • [4] Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report
    Goldman, S.
    Smith, L.
    Anderson, J. R.
    Perkins, S.
    Harrison, L.
    Geyer, M. B.
    Gross, T. G.
    Weinstein, H.
    Bergeron, S.
    Shiramizu, B.
    Sanger, W.
    Barth, M.
    Zhi, J.
    Cairo, M. S.
    LEUKEMIA, 2013, 27 (05) : 1174 - 1177
  • [5] Preliminary results of a phase II study of chemoimmunotherapy (rituximab plus FAB chemotherapy) in children and adolescents with intermediate risk B-cell NHL: A children's oncology group report
    Goldman, S.
    Lynch, J.
    Davenport, V.
    Perkins, S.
    Shiramizu, B.
    Sanger, W.
    Gross, T.
    Harrison, L.
    Bancroft, M.
    Cairo, M. S.
    ANNALS OF ONCOLOGY, 2008, 19 : 109 - 110
  • [6] The Efficacy of Rasburicase and Rituximab Combined with FAB Chemotherapy in Children and Adolescents with Newly Diagnosed Stage III/IV, BM plus and CNS plus Mature B-NHL: A Children's Oncology Group Report
    Goldman, Stanton
    Galardy, Paul J.
    Smith, Lynette
    Perkins, Sherrie L.
    Shiramizu, Bruce
    Gross, Thomas
    Sanger, Warren G.
    Harrison, Lauren
    Cairo, Mitchell S.
    BLOOD, 2011, 118 (21) : 1161 - 1162
  • [7] OUTCOME AND PHARMACOKINETIC (PK) ANALYSIS OF ADDING RITUXIMAB TO FAB CHEMOTHERAPY IN CHILDREN AND ADOLESCENTS WITH ADVANCED MATURE B-NHL/LEUKEMIA: A CHILDREN'S ONCOLOGY GROUP REPORT
    Goldman, Stan
    Smith, Lynette
    Perkins, Sherrie
    Shiramizu, Bruce
    Gross, Thomas
    Sanger, Warren
    Harrison, Lauren
    Cairo, Mitchell
    PEDIATRIC BLOOD & CANCER, 2011, 57 (05) : 737 - 738
  • [8] Preliminary Results of the Addition of Rasburicase to the Reduction Cycle and Rituximab to the Induction and Consolidation Cycles of FAB Group C Chemotherapy in Children and Adolescents with Advanced Stage (Bone Marrow +/-CNS) Mature B-Cell Non-Hodgkin Lymphoma (B-NHL): A Children's Oncology Group Report
    Goldman, Stanton
    Lynch, James
    Harrison, Lauren
    Gross, Thomas
    Shiramizu, Bruce
    Sanger, Warren
    Perkins, Sherrie L.
    Cairo, Mitchell S.
    BLOOD, 2009, 114 (22) : 48 - 48
  • [9] Safety, kinetics, and outcome following rituximab (R) in combination with FAB chemotherapy in children and adolescents (C plus A) with stage III/IV (Group B) and BM plus /CNS plus (Group C) mature B-NHL: A Children's Oncology Group report.
    Cairo, M. S.
    Lynch, J. C.
    Harrison, L.
    Perkins, S. L.
    Shiramizu, B.
    Gross, T. G.
    Sanger, W.
    Goldman, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] SAFETY AND PHARMACOKINETICS (PK) OF RITUXIMAB (R) IN COMBINATION WITH FAB CHEMOTHERAPY IN CHILDREN AND ADOLESCENTS (C+A) WITH STAGE III/IV MATURE B-NHL: A CHILDREN'S ONCOLOGY GROUP REPORT
    Barth, M. J.
    Goldman, S.
    Zhi, J.
    Smith, L.
    Perkins, S. L.
    Shiramizu, B.
    Gross, T.
    Sanger, W.
    Cairo, M. S.
    ANNALS OF ONCOLOGY, 2011, 22 : 112 - 112
12345